Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology
+$0.09 today
- Market cap
- $254.64M
- Beta
- 0.01
- P/E (TTM)
- 11.0
- EPS (TTM)
- $0.19
Volume 0.96M
Average 0.81M
PLX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Protalix BioTherapeutics, Inc.AMEX: PLX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $18.32M, compared with -$3.62M a year earlier. Trailing-twelve-month net income was $21.94M. Over 3 fiscal years it compounded at -23.8% a year.
Context
- Net income amounted to 12.5% of revenue in FY2025, up 7.0 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $21.54M (+426.1%) for the fiscal year ending Dec 2026, a step up from the -325.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $18.32M+1565.2% QoQ
- Last fiscal yearDec 2025
- -$6.6M-325.2% YoY
- LTMMar 2026
- $21.94M+461.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +606.1% | -609.7% | -1215.8 pp |
| 1 year | -325.2% | +426.1% | +751.3 pp |
| 3-year CAGR | -23.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (6.6M) USD
- Year-over-year change
- -325.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.6M) | -325.2% |
| FY2024 | 2024-12-31 | 2.93M | -64.7% |
| FY2023 | 2023-12-31 | 8.31M | +155.7% |
| FY2022 | 2022-12-31 | (14.93M) | +45.9% |
| FY2021 | 2021-12-31 | (27.58M) | — |
Net Income vs competitors
How PLX compares with its peers on the latest reported figures
- PLX's LTM Mar 2026 net income of $21.94M is the 2nd largest of the 4 companies compared; the peer median is $8.99M.
- Its year-over-year change of +461.3% is the highest of 4, against a peer median of +10.8%.
- Net income amounts to 28.7% of revenue for PLX, versus a peer median of 47.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $608.92M | +10.8% | -6.7% | 91.0% | |
| LTM Mar 2026 | $21.94M | +461.3% | -23.8% | 28.7% | |
| LTM Mar 2026 | $14.61M | +298.9% | -42.4% | 4.0% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | $8.99M | -70.4% | — | — |
| Peer median (excluding PLX) | $8.99M | +10.8% | -24.6% | 47.5% | |
Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.58M) | (14.93M) | 8.31M | 2.93M | (6.6M) |
| Depreciation & Amortization | 1.12M | 1.09M | 1.19M | 1.3M | 1.47M |
| Deferred Income Tax | 0 | 0 | (3.09M) | 236K | 340K |
| Stock-Based Compensation | 2.38M | 2.09M | 3.45M | 3.25M | 2.3M |
| Change in Working Capital | 9.9M | (12.02M) | (10.54M) | 811K | (10.1M) |
| Accounts Receivables | (1.03M) | (1.19M) | (428K) | 2.32M | (5.89M) |
| Inventory | (4.87M) | 1.15M | (2.24M) | (2.2M) | (4.49M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 15.81M | (11.97M) | (7.87M) | 692K | 277K |
| Other Non-Cash Items | 3.9M | (1.23M) | (638K) | 138K | 608K |
| Operating Cash Flow | (10.29M) | (25M) | (1.32M) | 8.67M | (11.99M) |
| Capital Expenditures | (1.46M) | (628K) | (1.15M) | (1.28M) | (1.64M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (37.84M) | (16M) | (20.42M) | (15M) | (702K) |
| Sales of Investments | 57.84M | 11M | 5M | 20.42M | 0 |
| Other Investing Activities | 380K | 593K | (142K) | 83K | (26K) |
| Investing Cash Flow | 18.92M | (5.04M) | (16.71M) | 4.22M | (2.37M) |
| Debt Repayment | (34.12M) | 0 | 0 | (20.42M) | 0 |
| Common Stock Issued | 46.2M | 8.24M | 23.95M | 3.63M | 9.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 2K | 712K | 0 | 0 |
| Financing Cash Flow | 12.08M | 8.24M | 24.67M | (16.79M) | 9.33M |
| Effect of Forex Changes | 6K | (77K) | (114K) | 25K | 655K |
| Net Change in Cash | 20.72M | (21.87M) | 6.52M | (3.87M) | (4.38M) |
| Free Cash Flow | (11.74M) | (25.63M) | (2.47M) | 7.39M | (13.63M) |
Protalix BioTherapeutics, Inc.
AMEX:PLX
Intrinsic Alpha fair value
Locked
Current Price
$3.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.